Why did Phase 1/2 FTO solid tumour clinical trial ($8.0 million) get the nod for the base case over Cardio-protection Phase 2b clinical trial in breast cancer patients ($7.5 million)?
I understand the FTO opportunity was discovered earlier, but recent commentary suggests cardio-protection is easier to recruit for and quicker to market all going well.
I hope the full case gets funded, and I think it will. I am taking up my allocation.
Ann: Race Oncology Share Purchase Plan Opens, page-401
-
- There are more pages in this discussion • 157 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |